Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Product Highlight - Spiolto Respimat

01 May 2018
SPIOLTO RESPIMAT - Tiotropium 2.5 mcg, Olodaterol 2.5 mcg inhalation soln - Boehringer Ingelheim

The Only LAMA/LABA with the active ingredient of SPIRIVA inside (Tiotropium)
Start SPIOLTO RESPIMAT early for your patients
• Starts working within 5 minutes after the first dose1
• Improves lung function, lasts for 24 hours1,2
• Consistently reduces the need for rescue medication beyond SPIRIVA7
• Contains SPIRIVA which has unsurpassed long-term data in EXACERBATION3
• Respimat is designed for deep lung deposition4-6 and all your patients need to do
  is breathe in naturally7

References:
1. SPIOLTO RESPIMAT Summary of Product Characteristics, March 2016
2. Beeh KM. Pulm Pharmacol Ther 2015;32:53-59.
3. Tashkin DP, et al. N Engl J Med 2008;21:159-168.
4. Newman SP, et al. Chest 1998;113:957-963
5. Pitcairn G, et al. J Aerosol Med 2005;18:264-272.
6. Peterson JB, et al. J Aerosol Med Pulm Drug Del 2008;21:159-168.
7. SPIRIVA RESPIMAT Summary of Product Characteristics, Nov 2017

Further information is available in section 3b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).